Market Place
Sourcing Support
Anthos Therapeutics Shares New AZALEA-TIMI 71 Study Analysis
16 Nov 2024 //
GLOBENEWSWIRE
Apotex`s Generics Rivaroxaban HCl Receives Approval in US
07 Nov 2024 //
FDA
Apopharma`s Generics Rivaroxaban Receives Tentative Approval in US
15 Oct 2024 //
FDA
Macleods Pharma`s Generics Rivaroxaban Receives Tentative Approval in US
11 Oct 2024 //
FDA
Acquired approval for manufacturing and marketing generic drugs
15 Aug 2024 //
PRESS RELEASE
Prinston Inc`s Generic Rivaroxaban Receives Tentative Approval in US
26 Jun 2024 //
FDA
Anthos: ~84% Eligible Patients Transitioned To Abelacimab In AZALEA Extension
06 Jun 2024 //
GLOBENEWSWIRE
J&J, Bristol Myers lose challenges to US drug price negotiation program
30 Apr 2024 //
REUTERS
Bayer`s patent for blood thinner Xarelto invalid, UK court rules
13 Apr 2024 //
REUTERS
Tiefenbacher Pharmaceuticals successfully prepares the launch of the anticoagulant Rivaroxaban.
09 Apr 2024 //
PRESS RELEASE
Ami Have Received Cep Approval For Rivaroxaban,Used An Anti-Coagulating Agent
08 Apr 2024 //
PRESS RELEASE
Findings Presented at ACC.24 Showed XARELTO Reduced the Risk
08 Apr 2024 //
PR NEWSWIRE
Breckenridge Pharma`s Generic Rivaroxaban Receives Approval in the U.S.
24 Jan 2024 //
FDA
Viatris` Rivaroxaban Receives Approval in Europe
13 Dec 2023 //
EMA
Tiefenbacher Launch anticoagulant Rivaroxaban in Canada
16 Nov 2023 //
PRESS RELEASE
New VOYAGER PAD Analyses Reinforce Benefit of XARELTO Plus Aspirin
14 Nov 2023 //
PRESS RELEASE
Anthos` Abelacimab, Demonstrated a 67% Reduction in Non-Major Bleeding
13 Nov 2023 //
BUSINESSWIRE
Taro`s Generic Rivaroxaban Receives Approval in the U.S.
03 Nov 2023 //
FDA
Study Confirming Reduction in Bleeding of Factor XI/XIa Inhibitor Abelacimab
26 Sep 2023 //
BUSINESSWIRE
Blackstone`s $250M bet beats Xarelto in phase 2 bleeding trial
18 Sep 2023 //
FIERCE BIOTECH
US details first 10 drugs subject to Medicare price negotiations
30 Aug 2023 //
REUTERS
Mylan`s Generic Rivaroxaban Receives Approval in the U.S.
14 Aug 2023 //
FDA
A convenient treatment option for Thromboembolic Events
10 Apr 2023 //
PRESS RELEASE
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO & Aspirin
05 Mar 2023 //
PR NEWSWIRE
Study confirms benefit of rivaroxaban for prevention venous thromboembolism
09 Jan 2023 //
PHARMACYTIMES
Alfa Enriches API Supply by Adding Lenalidomide, Parecoxib & Rivaroxaban
20 Dec 2022 //
DIGITALJOURNAL
COVID-19 inpatients do not gain from aspirin and rivaroxaban
29 Aug 2022 //
ESCARDIO
FDA Confirms Paragraph IV Patent Litigation for Xarelto (Rivaroxaban)
24 Aug 2022 //
FDA
As Nubeqa soars, Bayer`s Xarelto is struggling in China
05 Aug 2022 //
FIERCEPHARMA
Tiefenbacher Expands The Launch Of The Anticoagulant Medicine Rivaroxaban
15 Jul 2022 //
PRESS RELEASE
CVS Health returns BMS, Pfizer`s Eliquis to formulary
24 Jun 2022 //
FIERCEPHARMA
Bayer’s rivaroxaban receives Japanese approval in PAD
21 Jun 2022 //
PHARMABIZ
New Data From 2 Large Studies Show Effectiveness of DPI with XARELTO + Aspirin
23 May 2022 //
PRNEWSWIRE
Generics in China lead to a decline in Xarelto sales for Bayer
11 May 2022 //
FIERCEPHARMA
Data from VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO+Aspirin
01 Apr 2022 //
PRNEWSWIRE
Bayer gets FDA fast track status for next-generation blood thinner
11 Feb 2022 //
REUTERS
FDA Approves 2 New Indications for XARELTO for Blood Clots in Pediatric Patients
20 Dec 2021 //
PRNEWSWIRE
Bayer to Present Data from Voyager Pad (Xarelto) and Victoria Trial (Verquvo)
05 Nov 2021 //
PRESS RELEASE
Bayer wins EU patent extension for best-selling Xarelto drug
29 Oct 2021 //
REUTERS
What are the precautions for rivaroxaban tablets?
27 Oct 2021 //
PRESS RELEASE
New data in the European Heart Journal show ciraparantag reverses
04 Oct 2021 //
GLOBENEWSWIRE
New data in the European Heart Journal show ciraparantag reverses
04 Oct 2021 //
GLOBENEWSWIRE
Janssen reports positive Phase 3 paediatric data of Xarelto for blood clots
28 Sep 2021 //
CLINICALTRIALSARENA
J&J, Bayer`s Xarelto scores FDA nod in post-surgery artery disease
26 Aug 2021 //
FIERCEPHARMA
Immunocore`s bispecific gets speedy review with FDA, EMA; Xalud grabs $30M
24 Aug 2021 //
ENDPTS
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO®
24 Aug 2021 //
PRNEWSWIRE
AZ`s Pulmicort, Bayer`s Xarelto among losers in China`s VBP
25 Jun 2021 //
FIERCEPHARMA
Janssen Submits New Drug Application to U.S. FDA for XARELTO
23 Jun 2021 //
PRNEWSWIRE
Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin
17 May 2021 //
PRNEWSWIRE
J&J`s Xarelto charts long-term win in post-surgery PAD patients
17 May 2021 //
FIERCE PHARMA
Bayer`s post-Xarelto, post-Eylea life is better than expected
10 Mar 2021 //
FIERCEPHARMA
Bayer’s Xarelto approved in the UK
02 Feb 2021 //
PHARMATIMES
Bayer chief admits to unfillable revenue gap despite potential blockbuster
16 Jan 2021 //
FIERCE PHARMA
Natco Pharma launches anti blood clot medication, Rivaroxaban, in India
18 Dec 2020 //
ECONOMIC TIMES
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic
18 Nov 2020 //
NEJM
Rivaroxaban may be as effective as warfarin for bioprosthetic mitral valves, AF
16 Nov 2020 //
HEART
New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER
09 Nov 2020 //
PRNEWSWIRE
